A 39-week, open-label extension to CCOX189A2360, a 13-week, multicenter, randomized, double-blind, double-dummy, placebo-controlled, parallel trial of 2 different dose regimens of lumiracoxib (100 mg od and 200 mg od initial dose for two weeks followed by 100 mg od) in patients with primary knee osteoarthritis, using celecoxib (200 mg od) as a comparator

Trial Profile

A 39-week, open-label extension to CCOX189A2360, a 13-week, multicenter, randomized, double-blind, double-dummy, placebo-controlled, parallel trial of 2 different dose regimens of lumiracoxib (100 mg od and 200 mg od initial dose for two weeks followed by 100 mg od) in patients with primary knee osteoarthritis, using celecoxib (200 mg od) as a comparator

Completed
Phase of Trial: Phase III

Latest Information Update: 21 Jul 2007

At a glance

  • Drugs Celecoxib; Lumiracoxib
  • Indications Musculoskeletal pain; Osteoarthritis
  • Focus Adverse reactions
  • Sponsors Novartis
  • Most Recent Events

    • 21 Jul 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top